These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18929170)

  • 21. Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.
    Kymes SM; Plotzke MR; Kass MA; Boland MV; Gordon MO
    Arch Ophthalmol; 2010 May; 128(5):613-8. PubMed ID: 20457984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is more always better?
    Tuulonen A
    Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effective evaluation of the glaucoma suspect.
    Doshi A; Singh K
    Curr Opin Ophthalmol; 2007 Mar; 18(2):97-103. PubMed ID: 17301609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Steroid induced ocular hypertension and glaucoma].
    Călugăru D; Călugăru M
    Oftalmologia; 2009; 53(3):15-33. PubMed ID: 19899544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
    Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
    J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.
    Guedes RAP; Guedes VMP; Gomes CEM; Chaoubah A
    Medicine (Baltimore); 2016 Dec; 95(52):e5745. PubMed ID: 28033286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost, effectiveness, and cost-effectiveness.
    Diamond GA; Kaul S
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):49-54. PubMed ID: 20031812
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic impact of primary open-angle glaucoma in Australia.
    Dirani M; Crowston JG; Taylor PS; Moore PT; Rogers S; Pezzullo ML; Keeffe JE; Taylor HR
    Clin Exp Ophthalmol; 2011; 39(7):623-32. PubMed ID: 21631669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations in developing model-based economic evaluations of glaucoma treatment.
    Althin R; Grima DT; Dhawan R; Bernard LM
    J Glaucoma; 2006 Dec; 15(6):541-7. PubMed ID: 17106369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The limits of cost-effectiveness analysis.
    Weintraub WS; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):55-8. PubMed ID: 20031813
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost effectiveness of community-based physical activity interventions.
    Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
    Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bolstering Sisyphus.
    Van Buskirk EM
    J Glaucoma; 1998 Apr; 7(2):73-4. PubMed ID: 9559490
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma.
    Stein JD; Kim DD; Peck WW; Giannetti SM; Hutton DW
    Arch Ophthalmol; 2012 Apr; 130(4):497-505. PubMed ID: 22332202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of ocular hypertension: Hamlet's Lament revisited.
    Sommer A
    Arch Ophthalmol; 2010 Mar; 128(3):363-4. PubMed ID: 20212209
    [No Abstract]   [Full Text] [Related]  

  • 35. It is time for physicians to embrace cost-effectiveness and cost utility analysis research in the treatment of spinal pain.
    Dagenais S; Haldeman S; Polatin PB
    Spine J; 2005; 5(4):357-60. PubMed ID: 15996604
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of monitoring ocular hypertension based on a risk prediction tool.
    Wu H; Gazzard G; King A; Morgan J; Wright D; Crabb DP; Takwoingi Y; Azuara-Blanco A; Watson V; Hernández R
    BMJ Open Ophthalmol; 2024 Aug; 9(1):. PubMed ID: 39209325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model.
    Nordmann JP; Lafuma A; Deschaseaux C; Berdeaux G
    J Glaucoma; 2005 Dec; 14(6):463-9. PubMed ID: 16276278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Projected cost comparison of Trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan.
    Iordanous Y; Kent JS; Hutnik CM; Malvankar-Mehta MS
    J Glaucoma; 2014 Feb; 23(2):e112-8. PubMed ID: 23807348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.